9 Facts About Urolithin A and Why Menopause Researchers Are Paying Attention to Its Mitochondrial Effects
The fatigue of perimenopause isn't laziness and it isn't depression — it's something cellular, and for a long time there was no good language for it. When research started pointing to mitochondrial dysfunction as part of the picture, it finally felt like someone was looking in the right place. Urolithin A won't fix everything, but understanding why researchers are excited about it makes the exhaustion feel a little less mysterious.
Learn more about Rose →Mitochondria Are the Direct Target — and That Matters in Menopause
Estrogen receptors are present on mitochondrial membranes, and estrogen actively regulates mitochondrial biogenesis, efficiency, and antioxidant defense. As estrogen declines during perimenopause, mitochondrial function in muscle, brain, and metabolic tissue measurably deteriorates — which is one physiological reason fatigue and cognitive slowness can feel so structural. Urolithin A is one of the very few compounds with clinical evidence showing it directly improves mitochondrial health in humans, rather than just in cell cultures.
Urolithin A Is Not a Plant Chemical — It's Made by Your Gut
Urolithin A is not found in food directly; it is a postbiotic metabolite produced when gut bacteria break down ellagitannins, a class of polyphenols found in pomegranates, walnuts, and certain berries. The critical catch is that only roughly 30–40% of people have the gut microbiome composition capable of producing meaningful amounts of urolithin A from food alone, with the rest producing little or none. This is why researchers have studied oral urolithin A supplementation as a delivery route independent of gut microbiome variation.
Mitophagy Is the Specific Mechanism — and It's Genuinely Novel
Mitophagy is the cellular process by which damaged or dysfunctional mitochondria are identified, tagged, and cleared away so healthier mitochondria can take their place. Without adequate mitophagy, cells accumulate malfunctioning mitochondria that generate oxidative stress and produce energy inefficiently — a state that worsens with both aging and estrogen loss. Urolithin A is the first compound identified to activate mitophagy in humans via the PINK1-Parkin pathway, a finding confirmed in skeletal muscle biopsies in a 2019 randomized controlled trial published in Nature Metabolism.
The First Human RCT Showed Measurable Changes in Muscle Mitochondrial Gene Expression
The 2019 Nature Metabolism trial by Andreux and colleagues randomized sedentary older adults to urolithin A or placebo and took skeletal muscle biopsies at baseline and four weeks. The urolithin A group showed statistically significant upregulation of mitochondrial gene pathways and a measurable increase in cardiorespiratory fitness markers — changes that do not occur with placebo and are consistent with improved mitochondrial turnover. This matters because gene expression changes in muscle biopsy tissue are a meaningful proxy, not a surrogate endpoint invented for marketing purposes.
A 2022 RCT Found Improvements in Muscle Strength and Fatigue in Older Adults
A double-blind, placebo-controlled trial published in JAMA Network Open in 2022 followed 66 adults aged 65–90 taking 1,000 mg urolithin A daily for four months. The urolithin A group showed significantly greater improvements in muscle endurance (measured by hand grip and six-minute walk test) compared to placebo, alongside reductions in inflammatory markers including IL-6 and TNF-alpha. While the study population was older adults rather than perimenopausal women specifically, the mechanisms driving the benefit — mitochondrial dysfunction and low-grade inflammation — overlap substantially with the menopause transition.
The Anti-Inflammatory Effect Is Downstream of Mitochondrial Cleanup
Damaged mitochondria are a primary source of reactive oxygen species and pro-inflammatory signaling within cells; when mitophagy clears them efficiently, systemic inflammatory markers tend to fall as a consequence. The 2022 JAMA Network Open trial documented reductions in several circulating inflammatory proteins alongside the muscle function improvements, which is consistent with the mechanistic pathway rather than an independent anti-inflammatory drug effect. For women in perimenopause, where low-grade inflammation contributes to joint pain, fatigue, and metabolic shifts, this downstream effect is worth understanding.
Brain Mitochondria Are Also Implicated — Cognitive Data Is Emerging
Neuronal mitochondria are especially vulnerable to estrogen withdrawal because neurons have extremely high energy demands and limited capacity to compensate for mitochondrial inefficiency. Preclinical studies in animal models show urolithin A crosses the blood-brain barrier and activates mitophagy in hippocampal neurons, with associated improvements in learning and memory markers. Human cognitive outcome trials for urolithin A are not yet published, but the mechanistic plausibility is grounded in established neuroscience rather than extrapolation, making this an area to watch closely.
Urolithin A Has a Strong Safety Profile Across Human Trials
Multiple human trials, including a phase I dose-escalation study, have reported that urolithin A is well tolerated at doses up to 2,000 mg daily with no serious adverse events and no clinically significant changes in liver enzymes, kidney function, or blood panels. This is a meaningful data point because many compounds with interesting preclinical profiles fail at the safety stage; urolithin A has cleared first-in-human testing cleanly. Current evidence does not identify specific contraindications, though long-term safety data beyond six months in clinical trials is still limited.
The Research Gap Is Real: No Dedicated Perimenopause Trial Exists Yet
Every clinical trial to date has been conducted in older adults, sedentary populations, or patients with specific conditions — none has enrolled perimenopausal or early postmenopausal women as a primary population or measured outcomes like hot flashes, sleep architecture, or hormonal markers alongside mitochondrial endpoints. This means the connection between urolithin A's proven mechanisms and the specific symptom burden of menopause remains inferential, even if the inference is physiologically coherent. Honest evaluation requires acknowledging that gap rather than treating mechanism as proof of clinical benefit in this specific context.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.